FRCPC

Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate TT-816, a Novel Oral Immune Response Modifier, in Combination with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Wednesday, January 18, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, CB2, IO, Teone Church, Cancer, Immunity, Therapy, Neoplasm, Immunotherapy, Trial of the century, FRCPC, FACP, Hope, NK, Patient, Merck Sharp & Dohme Federal Credit Union, GPCR, PD-1, Merck & Co., Pembrolizumab, Pharmaceutical industry, Merck

The agreement is for the combination arm of Teon’s ongoing, two-armed, open-label, dose escalation and expansion clinical study and will evaluate Teon’s oral, immune response modifier, TT-816, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for patients with advanced solid tumors.

Key Points: 
  • The agreement is for the combination arm of Teon’s ongoing, two-armed, open-label, dose escalation and expansion clinical study and will evaluate Teon’s oral, immune response modifier, TT-816, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for patients with advanced solid tumors.
  • The study will include patients with many difficult-to-treat cancers with high unmet medical need who have not responded to the standard-of-care and may have limited treatment options.
  • “We are fortunate to have the opportunity to collaborate with Merck for this Phase 1/2 trial.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

BioAge Hosting Webcast to Discuss Newly Announced Phase 1b Data Demonstrating BGE-105 Significantly Improves Muscle Atrophy in Older Volunteers on Bed Rest and Detail Phase 2 Plans

Retrieved on: 
Wednesday, December 14, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Ageing, Therapy, Muscle atrophy, Duke University, UC, Human nutrition, APJ, Lung, MD, Conditional sentence, United States Senate Select Committee on Nutrition and Human Needs, Diaphragm, Doctor of Philosophy, Q&A, ICU, Toronto, Biomarker, Patient, Prevalence, Body composition, Ventilation, Degenerative disease, Research, Muscle, Atrophy, NLRP3, Kaiser Permanente, FRCPC, University Health Network, Kinemation, Khosla Ventures, University, KOL, Interest, Geriatrics, Mortality, Sarcopenia, University of California, Berkeley, Myopathy, Bed rest, Medicare, Tracheotomy, Risk, Pharmaceutical industry, Medical imaging, Dietary supplement, Medicine

William Evans, PhD is Adjunct Professor of Human Nutrition at UC Berkeley and Medicine (Geriatrics) at Duke University.

Key Points: 
  • William Evans, PhD is Adjunct Professor of Human Nutrition at UC Berkeley and Medicine (Geriatrics) at Duke University.
  • Previously, he was President of the Muscle and Health Division at KineMed and VP and Head of GlaxoSmithKlines Muscle Metabolism Discovery Performance Unit.
  • Phase 1b trial data released to date demonstrate that in healthy volunteers 65 and older on 10-day strict bed rest, BGE-105 prevented muscle atrophy as reflected by improvements in multiple parameters, including the dimensions of leg muscles, muscle quality, and muscle protein synthesis.
  • BioAge has multiple programs targeting muscle, immune, and brain aging, including the clinical-stage apelin receptor agonist BGE-105 and a differentiated CNS-penetrant NLRP3 inhibitor.

Triple Hair Group announces the launch of a telehealth platform for the diagnosis and treatment of androgenic alopecia

Retrieved on: 
Tuesday, November 15, 2022
Online, Hair loss, Diagnosis, Prescription, Physician, Patient, Hair, FRCPC, Woman, Medical device, Pharmaceutical industry

Hair Loss Rx Consult platform ( hairlossrxconsult.ca ) will provide hair loss condition diagnosis and recommend best treatment available.

Key Points: 
  • Hair Loss Rx Consult platform ( hairlossrxconsult.ca ) will provide hair loss condition diagnosis and recommend best treatment available.
  • MONTRAL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Triple Hair Group Inc. (Triple Hair or the Company), a company specializing in the development of innovative treatments for alopecia, is pleased to announce the launch of its own telehealth platform ( hairlossrxconsult.ca ) using technology from Oro Health.
  • This new solution will allow patients in Canada to obtain a diagnosis of their condition, prescription medications for hair regrowth, as well as information on alopecia.
  • Triple Hair Group Inc. is a Canadian biotechnology company specializing in developing innovative treatments for men and women suffering from alopecia.

Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors

Retrieved on: 
Tuesday, November 1, 2022
Research, Venture Capital, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, CB2, Ovarian cancer, CB1, CEO, GPCR, Inflammation, RCC, PD-1, Immunity, Lung, FIH, Clinical trial, FRCPC, Cancer, Brain, Renal cell carcinoma, Immunotherapy, Ovary, Immune system, Research, Safety, Hope, Company, Therapy, FACP, Pharmacokinetics, Patient, NK, NSCLC, Phase 1, Pharmaceutical industry, Vaccine, Teone Church

The study will include patients with advanced solid tumors with high unmet medical need who have not responded to the standard-of-care and may have no more treatment options.

Key Points: 
  • The study will include patients with advanced solid tumors with high unmet medical need who have not responded to the standard-of-care and may have no more treatment options.
  • As a novel checkpoint inhibitor with unique mechanisms of action, I am hopeful about the role of TT-816 in the treatment landscape.
  • The Phase 1/2 clinical trial is actively recruiting patients with advanced solid tumors in several sites.
  • Teon has an ongoing Phase 1/2 trial evaluating TT-816, a cannabinoid CB2 antagonist and a Phase1/2 trial evaluating TT-702, an A2B receptor-specific antagonist.

Quarterly Activities Report for September 2022

Retrieved on: 
Tuesday, October 25, 2022
R, Executive, Quarter, Contract research organization, Central nervous system, Chemistry, GLOBE, Blue star, Annual report, BNC210, Doctor of Philosophy, FRCPC, Patient, KOL, Company, Corporate governance, Anxiety disorder, Post-traumatic stress disorder, BNO, MPH, Research, U.S. Securities and Exchange Commission, Bionomics, ASX, University of California, San Diego Performance-Based Skills Assessment, Social anxiety disorder, Conference, University, SAD, EDT, Medical device, Health insurance, Online gambling, Renewable energy, Pharmaceutical industry, Marketing, MD

On 29 July 2022, Bionomics released its Appendix 4C Quarterly Cashflow Report for the quarter ended 30 June 2022.

Key Points: 
  • On 29 July 2022, Bionomics released its Appendix 4C Quarterly Cashflow Report for the quarter ended 30 June 2022.
  • On 25 August 2022, Bionomics released its Appendix 4E and Full Year Financial Statements for the year ended 30 June 2022.
  • On 6 October 2022, the Company filed its 2022 Annual Report.
  • Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the financial year ended 30 June 2022.

Elected Leaders Began Terms at the 2022 ASDS Annual Meeting

Retrieved on: 
Monday, October 24, 2022
Physician, Resident Representative, Communication, Disease, Growth, Machine learning, Dermatology, Annual report, Society, Patient, Annual general meeting, Private practice, Resident, FRCPC, Technology, University, Blemish (album), Hair, Industry, Health, Board, Awareness, Incidence, Social media, Patient safety, Skin, GLOBE, Environment, Board of directors, ASDS, Beauty, Skin cancer, Health insurance, Management, Medical device, Hospital, Dentistry, Director, MD

Rolling Meadows, IL, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Results of the 2022 election were announced on Saturday, Oct. 8 at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Denver, Colorado.

Key Points: 
  • Rolling Meadows, IL, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Results of the 2022 election were announced on Saturday, Oct. 8 at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Denver, Colorado.
  • The new terms began at the Annual Membership Meeting, where accomplishments and initiatives for ongoing growth were also shared.
  • She presented the 2022 financial report during the Annual Membership Meeting and will provide final analysis in the 2022 ASDS/A Annual Report.
  • ASDS members are recognized as leaders in the field of cosmetic and medically necessary skin surgery.

ASDS Recognizes 2022 Award Recipients at Annual Membership Meeting

Retrieved on: 
Monday, October 24, 2022
Resident, Virginia House of Delegates, Minnesota Department of Employment and Economic Development, Annual, Program, Delegate, University, Hair, Treatment, Health, Merkel cell, PATH (global health organization), Mohs surgery, Beauty, Skin care, Plasma, MBA, Annual general meeting, FRCPC, Knowledge, Blemish (album), Incidence, Lecture, Medicine, Skin, GLOBE, African, Leadership, Time, Washington Institute, ASDS, Society, Research, Cutting edge, Georgetown University Medical Center, Instagram, HIV, House, Skin cancer, Disease, JD, Education, Merkel-cell carcinoma, Partnership, Human, Systematic review, Social media, Faculty, Cross, Dentistry, Veterinary medicine, Pharmaceutical industry, Hospital, Dermatology, DRS, MD, Patient

Rolling Meadows, IL, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Top dermatologists were recognized at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Denver, Colorado, during the Annual Membership Meeting on Saturday, Oct. 8.

Key Points: 
  • Rolling Meadows, IL, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Top dermatologists were recognized at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Denver, Colorado, during the Annual Membership Meeting on Saturday, Oct. 8.
  • ASDS / ASDSA Staff For the contributions ASDS / ASDSA staff members make every day that support the success of the organization.
  • He accepted his award at the Annual ASDS Gala on Saturday, Oct. 8.
  • Sean Wu, MD, received the highest scoring for his outstanding ASDS Annual Meeting abstract submission, Vision Loss After Platelet-Rich Plasma Injection: A Systematic Review of Medical Literature.

American Society of Echocardiography Invests in Joint Research Initiative to Help Patients Suffering from Wide-Reaching Form of Heart Failure

Retrieved on: 
Thursday, September 29, 2022
National, ASE, Center, Twitter, Nursing, NHLBI, National Heart, Lung, and Blood Institute, Biomedical Research, Heart failure with preserved ejection fraction, LinkedIn, Veterinarian, FNIH, Society, Heart failure, Social media, FRCPC, Massachusetts General Hospital, Program, Patient, Clinical trial, Physician, Quality of life, Human services, Private sector, Board of directors, Foundation, AMP, Board, Research, GLOBE, Medicine, Congress, Mortality, FACC, NIH, HF, Education, Medical imaging, Pharmaceutical industry, MD, Facebook

ASE is one of the key partner organizations in a joint research initiative that aims to identify more precise treatment strategies for patients suffering from heart failure with preserved ejection fraction (HFpEF).

Key Points: 
  • ASE is one of the key partner organizations in a joint research initiative that aims to identify more precise treatment strategies for patients suffering from heart failure with preserved ejection fraction (HFpEF).
  • HFpEF is a common form of heart failure that is difficult to detect.
  • In the last 25 years, the Society and its Foundation have contributed more than $7.3 million to cardiovascular health research.
  • The American Society of Echocardiography (ASE) is the Society for Cardiovascular Ultrasound Professionals.

New Canadian Surveys Highlight Influenza Education, Discussions with Healthcare Professionals, and Ease of Access as Critical to Supporting Vaccination Uptake

Retrieved on: 
Thursday, September 29, 2022
Adult, Hospital, Vaccine-preventable diseases, CSL, ASX, Child, COVID-19, Risk, Haemophilia, Disease, Control, Research, Role, National Institute on Aging, CSL Behring, Intention, Vaccination, MF59, Medical Affairs Bureau, Influenza vaccine, FRCPC, Infection, Patient, Statistics Canada, Immunodeficiency, Doctor of Philosophy, Vaccine, HCP, National Advisory Committee on Immunization, NACI, Death, HCPS, Ageing, Parent, Health policy, Biotechnology, R, Influenza, CSL Limited, National Institute, MD, Immunization

"Particularly among more vulnerable populations, such as older adults, we need to think creatively about how to improve access to influenza vaccines.

Key Points: 
  • "Particularly among more vulnerable populations, such as older adults, we need to think creatively about how to improve access to influenza vaccines.
  • Understanding Influenza Vaccination Uptake During the COVID-19 Pandemic in Canada (Poster Exhibition: Monday, September 26, 2022, #P-189).
  • The objectives of the survey included better understanding the impact of the COVID-19 pandemic on influenza vaccination intentions and uptake and how the influenza vaccination gap in Canada can be improved.
  • Pediatric Influenza Vaccination Uptake and Intentions in Canada and the Role of Health Care Providers (Poster Exhibition: Monday, September 26, 2022, #P-187).

Updated diabetes guideline released by the American Association of Clinical Endocrinology features the latest state-of-the-science in diabetes care

Retrieved on: 
Tuesday, September 27, 2022
Prediabetes, Health, Safety, Chronic kidney disease, COVID-19, Risk, Peripheral neuropathy, Diabetes, FDA, MD, FACP, Infertility, Knowledge, Vaccination, Obesity, MACE, American Association, Heart failure, FRCPC, Glycemia, Hypertension, Person, DRS, Environment, Endocrinology, Sleep hygiene, Patient, Cancer, Retinopathy, MBA, Quality of life, Female, Dyslipidemia, Male, Guideline, Global health, FACE, Diagnosis, Doctor of Philosophy, Cardiovascular disease, Hypoglycemia, AACE, Conference, Association, Multimedia, Depression, Hyperglycemia, Medical device, Pharmaceutical industry

JACKSONVILLE, Fla., Sept. 27, 2022 /PRNewswire/ -- The American Association of Clinical Endocrinology (AACE) is proud to announce the release of its updated guideline for the care and management of people with or at risk for diabetes mellitus.

Key Points: 
  • JACKSONVILLE, Fla., Sept. 27, 2022 /PRNewswire/ -- The American Association of Clinical Endocrinology (AACE) is proud to announce the release of its updated guideline for the care and management of people with or at risk for diabetes mellitus.
  • The guideline features 170 updated and new evidence-based clinical practice recommendations for diabetes at every stage, including prevention, diagnosis, and treatment.
  • "The guideline is framed to support person-centered, team-based clinical decision-making, which importantly puts the patient at the center to improve care for people with prediabetes and diabetes."
  • The 2022 guideline update synthesizes thousands of articles to provide health care professionals with the latest evidence-based information on the total care of diabetes.